Tennessee Oncology-Nashville/Sarah Cannon Research Institute is a clinical research site located in Nashville, Tennessee, United States 37203.
Crixeo Health Trust Score: 69/100 (FAIR). This profile has not yet been claimed by the site owner.
Tennessee Oncology-Nashville/Sarah Cannon Research Institute has participated in 7 clinical trials with 1 currently active.
Therapeutic areas: Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous.
Sponsors: Seagen Inc., Seagen, a wholly owned subsidiary of Pfizer.
Trust Score: 69/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
Tennessee Oncology-Nashville/Sarah Cannon Research Institute has a Crixeo Trust Score of 69/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Tennessee Oncology-Nashville/Sarah Cannon Research Institute has 7 clinical trials on record, with 1 currently active. Their work covers Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous.
Tennessee Oncology-Nashville/Sarah Cannon Research Institute has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.